Teleflex Incorporated (TFX - Free Report) recently released favorable results of multiple studies on the company’s minimally invasive treatment for enlarged prostate, also known as BPH (benign prostatic hyperplasia). Data demonstrating the effectiveness of the UroLift was presented at the 2019 European Association of Urology (EUA) meeting.
What is BPH?
BPH is a common noncancerous condition with certain severe urinary symptoms. This can lead to loss of productivity, depression, interrupted sleep and a deteriorated quality of life. Per Urology Care Foundation, the official foundation of the American Urology Association, the prostate goes through two main growth periods. The first phase occurs early in puberty while the second begins around the age of 25 and persists through the better part of a man's life.
UroLift at a Glance
This is an FDA-approved minimally invasive technology to treat lower urinary tract symptoms of BPH. The UroLifts are permanent implants that provide relief to afflicted patients from prostate obstruction and opens the urethra directly without cutting, heating or removing prostate tissue.
The Study Details
One of the studies highlighted the real-world retrospective data on 30 men complaining of urinary retention treated with the UroLift System. Per the findings, the UroLift System showed its efficacy in a very complex cohort with 83% men being urinary retention catheter-free in less than three days. Outcomes also confirmed a significant improvement in prostatic symptom score, quality of life and post-void residuals, displaying the effectiveness of the UroLift System treatment for men with BPH.
Three other presentations on UroLift were made by Teleflex at EAU. According to TeleFlex, all the four findings affirm the safety and efficacy of the UroLift System as a minimally invasive treatment, capable of providing patients with a lasting relief from the symptoms of BPH.
Scope for UroLift in the BPH Treatment Market
Benign prostatic hyperplasia often occurs during the second growth phase and is very common in aging men (about half of all men aged between 51 and 60 years have BPH and again up to 90% men above 80 have BPH).
With the demography inclining toward aging population, the market for BPH stands enormous and expanding. Per data provided by TeleFlex, BPH affects more than 40 million men across the United States alone. This statistic might inflict fears about permanent bladder damage if left untreated.
Undoubtedly, the latest findings on UroLift should drive the product adoption rate within TeleFlex’ Interventional Urology business.
Share Price Performance
Over the past year, shares of Teleflex have outperformed its industry. The stock has rallied 20.6% compared with the industry’s 16.3% rise.
Zacks Rank & Key Picks
TeleFlex currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Veeva Systems Inc. (VEEV - Free Report) and Hologic, Inc. (HOLX - Free Report) .
Integer Holdings projects an earnings growth rate of 31.2% for the first quarter of 2019. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva Systems’ long-term earnings growth rate is expected at 14.8%. The stock has a Zacks Rank of 2.
Hologic’s long-term earnings growth rate is estimated at 8.9%. The stock presently is a Zacks #2 Ranked player.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>